Most Read Articles
24 Aug 2016

Roshini Claire Anthony spoke with Adjunct Associate Professor Gamaliel Tan, head and senior orthopaedic consultant at Ng Teng Fong Hospital in Singapore, on how GPs can help diagnose and treat lower back pain.

26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Teng Sung Shin, Joyce Lam Ching Mei, 03 Sep 2018
Bleeding disorders in children can be divided into acquired and congenital conditions, with the acquired being far more common than the congenital. Clinical bleeding manifestations can vary in severity. Identifying the root cause early is crucial to control and halt bleeding as well as to prevent the risk of future bleeding in a vulnerable age group. This can be achieved by a thorough and salient history, physical evaluation, and appropriate investigations. This review will describe the common causes of bleeding disorders in children and will suggest an approach to the workup and diagnosis of such disorders.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Prolonged exposure to high-dose atorvastatin may suppress prostate cancer proliferation

23 Nov 2018

Long exposure to atorvastatin appears to slightly reduce prostate cancer proliferation rates in patients scheduled for radical prostatectomy, according to a recent study.

The study included 158 statin-naïve prostate cancer patients who were randomly assigned to receive either 80 mg atorvastatin (n=80; median age 64 years) or placebo (n=78; median age 63 years) daily for a median duration of 27 days. Baseline lifestyle habits, comorbidities and tumour characteristics were comparable between both treatment arms.

Overall, no significant difference in the median levels of tumour proliferation marker Ki-67 was observed between the two treatment arms (placebo vs atorvastatin: 1.98 vs 1.78; percent difference, –10 percent; p=0.9). However, effect modification by exposure time was statistically significant (p=0.032).

Moreover, after exposure for 28 days, there was a borderline-significant 14.1-percent reduction in Ki-67 levels in the atorvastatin arm (median level: 1.70; p=0.056).

Median levels of prostate-specific antigen (PSA) were significantly comparable between the placebo and atorvastatin arms (–0.2 vs –0.4 ng/mL; difference, –0.2 ng/mL; p=0.2). While treatment duration had no effect on PSA levels, atorvastatin was significantly superior among high-grade cases (p=0.024).

The treatment had no significant effect on the combined inflammation score, as well as on inflammation on separate tissue compartments. In high-grade cases, atorvastatin significantly suppressed intraprostatic inflammation.

Overall, the findings showed that while short-term, high-dose intervention with atorvastatin was well-tolerated, it yielded no significant beneficial effects, except in patients with high-grade malignancies. On the other hand, extended exposure successfully reduced prostate cancer proliferation.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
24 Aug 2016

Roshini Claire Anthony spoke with Adjunct Associate Professor Gamaliel Tan, head and senior orthopaedic consultant at Ng Teng Fong Hospital in Singapore, on how GPs can help diagnose and treat lower back pain.

26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Teng Sung Shin, Joyce Lam Ching Mei, 03 Sep 2018
Bleeding disorders in children can be divided into acquired and congenital conditions, with the acquired being far more common than the congenital. Clinical bleeding manifestations can vary in severity. Identifying the root cause early is crucial to control and halt bleeding as well as to prevent the risk of future bleeding in a vulnerable age group. This can be achieved by a thorough and salient history, physical evaluation, and appropriate investigations. This review will describe the common causes of bleeding disorders in children and will suggest an approach to the workup and diagnosis of such disorders.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.